DDInter909 DDInter1008
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Imatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Imatinib {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Imatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Imatinib {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Imatinib {u} (Compound) causes {v} (Side Effect) Eye irritation
Eye irritation {u} (Side Effect) is caused by {v} (Compound) Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Imatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Imatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) ALDOC
ALDOC {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Imatinib (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Ketoconazole (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Imatinib (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Imatinib (Compound) causes Eye irritation (Side Effect) and Eye irritation (Side Effect) is caused by Posaconazole (Compound) and Posaconazole (Compound) resembles Ketoconazole (Compound)
Imatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound) and Posaconazole (Compound) resembles Ketoconazole (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Imatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ALDOC (Gene) and ALDOC (Gene) is upregulated by Ketoconazole (Compound)